Insulin aspart
Clinical data | |
---|---|
Trade names | NovoLog, NovoRapid, Fiasp, others |
Biosimilars | Kirsty,[1] Trurapi,[2] Truvelog[3] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605013 |
License data | |
Pregnancy category | |
intravenous | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C256H381N65O79S6 |
Molar mass | 5825.60 g·mol−1 |
(what is this?) (verify) |
Insulin aspart, sold under the brand name NovoLog, among others, is a
Common side effects include
Insulin aspart was approved for medical use in the United States in 2000.[17] In 2021, it was the 71st most commonly prescribed medication in the United States, with more than 9 million prescriptions.[19][20] Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome.[21] This yeast then makes the insulin, which is harvested from the bioreactor.[22]
Medical uses
Insulin aspart is
Onset of action
The onset of action is approximately fifteen minutes, the peak action is reached in 45–90 minutes, and the duration is 3–5 hours.[13]
Side effects
The safety of insulin aspart in people with diabetes is no different from that of regular insulin. The side effects that are commonly associated with insulin therapy include: allergic reactions, injection site irritation, rashes, and
Formulations
Insulin aspart can be used in an
Insulin aspart has a more rapid onset, and a shorter duration of activity than normal human insulin.[26] Insulin aspart can also be used with external insulin pumps.[13]
Variations
NovoLog Mix 70/30 is a product which contains 30% insulin aspart and 70% insulin aspart protamine.[14] The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection.[14] The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day.[27]
NovoLog Mix is marketed to be used with the Novo Nordisk FlexPen.[28] The onset of action is less than 30 minutes, the peak action is reached in 1–4 hours, and the duration is less than 24 hours.[29] NovoLog Mix is marketed in some countries as NovoMix 30.[30][15]
NovoRapid is produced in
A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability.[31][32][33]
Biosimilars
On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kixelle, intended for the treatment of diabetes mellitus.[34] The applicant for this medicinal product is Mylan IRE Healthcare Limited. Kixelle was approved for medical use in the European Union in February 2021.[35] Kixelle was renamed to Kirsty.[1]
Trurapi was approved for medical use in Canada in October 2020.[36]
Truvelog and Truvelog Solostar were approved for medical use in Australia in October 2020.[3][7]
In October 2021, Kirsty was approved for medical use in Canada.[37]
On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Truvelog Mix 30, intended for the treatment of diabetes mellitus.[38] The applicant for this medicinal product is sanofi-aventis groupe.[38] It was approved for medical use in the European Union in April 2022.[16][39]
Society and culture
As of 2018[update], there is a lack of compelling evidence to conclude superiority of insulin aspart over human insulin in
References
- ^ a b c "Kirsty EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 15 September 2021. Retrieved 14 September 2021.
- ^ "Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
- ^ a b c d "Truvelog". Therapeutic Goods Administration (TGA). 23 October 2020. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
- ^ a b "Insulin aspart Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ a b "Australian Public Assessment Report for Insulin aspart" (PDF). Therapeutic Goods Administration (TGA). March 2021. Archived from the original (PDF) on 24 June 2021.
- ^ "Australian Public Assessment Report for Insulin aspart (rys)" (PDF). Therapeutic Goods Administration (TGA). August 2021. Archived from the original (PDF) on 5 February 2022.
- ^ a b "Truvelog Solostar ARTG". Therapeutic Goods Administration (TGA). Archived from the original on 13 June 2021. Retrieved 12 June 2021.
- ^ "Regulatory Decision Summary - Fiasp". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
- ^ "Regulatory Decision Summary - Trurapi". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
- ^ "Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ a b "NovoRapid 100 units/ml in a vial - Summary of Product Characteristics (SmPC)". (emc). 25 May 2018. Archived from the original on 16 January 2021. Retrieved 9 September 2020.
- ^ a b "Fiasp- insulin aspart injection injection, solution". DailyMed. 19 December 2019. Archived from the original on 13 November 2020. Retrieved 12 November 2020.
- ^ a b c d "NovoLog- insulin aspart injection, solution Insulin Diluting Medium For NovoLog- water injection injection, solution". DailyMed. 15 November 2019. Archived from the original on 12 November 2020. Retrieved 12 November 2020.
- ^ a b c "NovoLog Mix 70/30- insulin aspart injection, suspension". DailyMed. 15 November 2019. Archived from the original on 29 September 2020. Retrieved 12 November 2020.
- ^ a b "NovoMix EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 13 April 2020. Retrieved 12 April 2020.
- ^ a b "Truvelog Mix 30 EPAR". European Medicines Agency. 23 February 2022. Archived from the original on 17 June 2022. Retrieved 16 June 2022.
- ^ a b c d e f g h "Insulin Aspart Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ISBN 9781441964182. Archivedfrom the original on 20 April 2021. Retrieved 11 September 2020.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Insulin Aspart - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ISBN 9781420039832. Archivedfrom the original on 20 April 2021. Retrieved 11 September 2020.
- ISBN 9783527677566. Archivedfrom the original on 20 April 2021. Retrieved 11 September 2020.
- ^ "Novolog: most FAQ". Archived from the original on 3 October 2011. Retrieved 18 April 2011.
- ^ "Novolog: insulin aspart (rDNA origin) injection" (PDF). Novo Nordisk. Archived (PDF) from the original on 22 March 2011. Retrieved 18 April 2011.
- ^ "Aspart insulin (rDNA origin) injection". Archived from the original on 10 June 2007. Retrieved 8 June 2007.
- ^ "Novolog: insulin aspart" (PDF). Food and Drug Administration. Archived (PDF) from the original on 17 May 2017. Retrieved 16 December 2019.
- ^ "NovoLog Mix 70/30". Rx List. 6 August 2008. Archived from the original on 20 April 2009.
- ^ "NovoLog Mix 70/30". Novo Nordisk. 2008. Archived from the original on 8 May 2009.
- ISBN 978-1-4200-4437-9.
- ^ "NovoMix 30 FlexPen 100 units/ml - Summary of Product Characteristics (SmPC)". (emc). 27 March 2019. Archived from the original on 13 April 2020. Retrieved 12 April 2020.
- PMID 35746893.
- PMID 31144428.
- PMID 31485918.
- ^ "Kixelle: Pending EC decision". European Medicines Agency (EMA). 10 December 2020. Archived from the original on 12 December 2020. Retrieved 12 December 2020.
- ^ "Kixelle EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 29 June 2021. Retrieved 16 March 2021.
- ^ "Summary Basis of Decision (SBD) for Trurapi". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
- ^ "Summary Basis of Decision (SBD) for Kirsty". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
- ^ a b "Truvelog Mix 30: Pending EC decision". European Medicines Agency. 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Truvelog Mix 30 Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- PMID 30556900.
- S2CID 30709912.
- PMID 27362975.